Results 51 to 60 of about 3,179,450 (287)

Liquid-based biomarkers in breast cancer: looking beyond the blood

Journal of Translational Medicine, 2023
In recent decades, using circulating tumor cell (CTC), circulating tumor DNA (ctDNA), circulating tumor RNA (ctRNA), exosomes and etc. as liquid biomarkers has received enormous attention in various tumors, including breast cancer (BC).
You Shuai, Zhonghua Ma, Jie Ju, Tong Wei, Songlin Gao, Yikun Kang, Zixuan Yang, Xue Wang, Jian Yue, Peng Yuan   +9 more
doaj   +1 more source

Metastatic niche shaped by host factors influences disseminated cancer cell fate

FEBS Letters, EarlyView.
Metastasis is shaped not only by cancer cells but also by the environments they encounter. This review explores how factors such as aging, diet, the microbiome, lifestyle, and environmental exposures remodel organ‐specific niches in the lung, liver, bone, and brain, influencing where metastatic cells survive, remain dormant, or grow, and ultimately ...
Gwennan Delyth Ward, Álvaro Ruiz‐Tabas, Patricia Altea‐Manzano   +2 more
wiley   +1 more source

circulating tumor DNA in the immediate post-operative setting

Annals of Surgical Oncology, 2023
Abstract Background Circulating tumor DNA (ctDNA) has emerged as an accurate real-time biomarker of disease status across most solid tumor types. Most studies evaluating the utility of ctDNA have focused on time points weeks to months after surgery, which for many cancer types, is significantly later
Vasileios Efthymiou, Natalia Queenan, Markus Haas, Saskia Naegele, Deborah Goss, Daniel L. Faden   +5 more
openaire   +3 more sources

Liquid biopsy in gallbladder carcinoma: Current evidence and future prospective

The Journal of Liquid Biopsy
Although there have been significant advances in the early detection and treatment of gallbladder cancer (GBC), it is still considered a leading cause of morbidity and mortality. Molecular profiling of tumors is generally performed using samples obtained
Sridhar Mishra, Swati Kumari, Nuzhat Husain   +2 more
doaj   +1 more source

Potential of circulating tumor DNA to refine immunotherapy

, 2023
Circulating tumor DNA (ctDNA) is a noninvasive strategy to disease assessment of minimal residual disease and treatment response for advanced cancer. ctDNA is emerging as a tool for use in clinical practice and informing novel clinical trial designs in ...
Luke, Jason J., Lee, RJ; id_orcid, Rebecca J. Lee, Jason J. Luke   +3 more
core   +1 more source

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

FEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy [PDF]

Cancer Discovery, 2016
Abstract “Liquid biopsy” focusing on the analysis of circulating tumor cells (CTC) and circulating cell-free tumor DNA (ctDNA) in the blood of patients with cancer has received enormous attention because of its obvious clinical implications for personalized medicine. Analyses of CTCs and ctDNA have paved new diagnostic avenues and are,
C. Alix-Panabieres, K. Pantel
openaire   +2 more sources

Evaluation of exome sequencing to estimate tumor burden in plasma. [PDF]

PLoS ONE, 2014
Accurate estimation of systemic tumor load from the blood of cancer patients has enormous potential. One avenue is to measure the presence of cell-free circulating tumor DNA in plasma.
Daniel Klevebring, Mårten Neiman, Simon Sundling, Louise Eriksson, Eva Darai Ramqvist, Fuat Celebioglu, Kamila Czene, Per Hall, Lars Egevad, Henrik Grönberg, Johan Lindberg   +10 more
doaj   +1 more source

Significance of Studying Circulating Tumor Cells

, 2016
Circulating Tumor Cells (CTC) are tumor cells released into blood. They are considered the pivotal component of the metastatic cascade and are being extensively studied only in the last decade or so.
Richard J. Cote, Cote, Richard J, Zheng Ao, Datar, Ram H, Ram H. Datar, Ao, Zheng   +5 more
core   +1 more source

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

Molecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce, Simone Bini, Marialuisa Sponziello, Giorgio Grani, Giulia Fiscon, Paola Paci, Lorenzo Farina, Rosa Falcone, Valentina Maggisano, Sebastiano Filetti, Cosimo Durante, Antonella Verrienti   +11 more
wiley   +1 more source